Back to Search
Start Over
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
- Source :
- The Lancet Haematology; June 2024, Vol. 11 Issue: 6 pe415-e424, 10p
- Publication Year :
- 2024
-
Abstract
- Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk.
Details
- Language :
- English
- ISSN :
- 23523026
- Volume :
- 11
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- The Lancet Haematology
- Publication Type :
- Periodical
- Accession number :
- ejs66460603
- Full Text :
- https://doi.org/10.1016/S2352-3026(24)00070-X